[S-24] Potential disease modifying therapies for Parkinson disease

[S-24-3] パーキンソン病のゲノムワイド関連解析データを使用したインシリコ薬剤スクリーニング

戸田 達史 (東京大学病院 神経内科)

The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying degeneration to treatments aiming at compensating lost neuronal functions. It is the ultimate goal of Parkinson disease treatment, although all attempts to develop effective disease-modifying therapy have failed to date. Many reasons have been proposed for these failures including our poor understanding of disease pathogenesis and the lack of sensitive surrogate markers of PD. Moreover, several observations suggest that the PD is not a single disease, but syndrome based on a variety of pathophysiological mechanisms. However, recently several promising new approaches have been reported and attracted attentions. The aim of this symposium is to elucidate true possibilities and real limitations of such novel trials.

2018- President, Japanese Society of Neurology
2017- Professor, Department of Neurology, Graduate School of Medicine, University of Tokyo.
2009-17 Professor, Division of Neurology / Molecular Brain Science, Kobe University Graduate School of Medicine
2000-09 Professor, Division of Clinical Genetics, Department of Medical Genetics, Osaka University Graduate School of Medicine
1996-2000 Associate Professor, Human Genome Center, Institute of Medical Science, University of Tokyo
1994-96 Assistant Professor, Department of Human Genetics, Graduate School of Medicine, University of Tokyo
1985-94 Medical Doctor, Department of Neurology, University of Tokyo
1985 graduated from University of Tokyo, Faculty of Medicine

Member of the Science Council of Japan

1999 Award of Japanese Society of Human Genetics
2002 Award of Societas Neurologica Japonica
2008 Asahi Award
2009 Award from Japanese Minister of Education, Culture, Sports, Science and Technology
2012 Tokizane Memorial Award
2017 Japan Academy Prize